Genmab — December 2019

[E_L]

Updated analysis of MAIA: D-Rd continues to beat Rd in transplant-ineligible NDMM https://www.youtube.com/watch?v=NfBDpLjI2mM

[gdn55]

Enig Nike. Jeg har købt 30 stk.mere. Der er jo intet sket med Genmab siden i fredags.

[bongobob]

Hvis ikke jeg havde brugt pengene på sprut ville jeg genkøbe den aktie jeg solgte forleden. Kurtagen er betalt ved kurs 1571

[gdn55]

Lad os nu se ved lukke tid, der kunne jo komme
gode meldinger i nat. Lige noget for spekulanterne.

[Solsen]

The meeting will include presentations by independent experts on data from the Phase I/II DuoBody-CD3xCD20 (GEN3013) study as well as various daratumumab studies presented at the 61st Annual Meeting of the American Society of Hematology (ASH).

[Solsen]

Spændende de har fokus på CD20/CD3 på R&D mødet efter Ash.

[Solsen]

Man hiver vel ikke en flok eksperter ind og snakker om om noget skrammel.

[Sukkeralf]

De kunne passende lave en deal på CD20/CD3 og DuoHexaCD37 - og så få lidt fart over feltet, så man ikke kommer for langt bagud

[Solsen]

Mon ikke man arbejder på det...

[Solsen]

vi kan vel håbe at se det først i det nye år.

[Bulder]

Jeg ville godt snart se noget poc på hexabody.

[E_L]

I am a bit surprised they don't mention hex-cd38...?

[E_L]

from Q&A - Jan Van de Winkel We will present a very impressive preclnical data set at the ASH conference in early
December showing that HexaBody CD38 can effectively kill tumors that are not
sensitive to Daratumumab...
Jan Van de Winkel A number of tumors will be presented in Orlando and we certainly think that HexaBody
CD38 could well provide an option for treatment of solid cancers.

[Sukkeralf]

Ja man er ikke helt oppe og ringe - nogen der ved om lever tox problemerne i DR5/DR5 programmet kan være relateret dertil ?

[Solsen]

Dont you think we get an update on the pipeline in generel.

[Sukkeralf]

We will: Genmab speakers will also discuss the company’s pipeline, progress and key goals for 2020

[Sukkeralf]

for sure hexaCD38 will be mentioned

[Sukkeralf]

its a clinical candidate next year

[Solsen]

I think we have to look at DR5 as a lottery ticket.

[Sukkeralf]

Yes but hopefully its the target thats still a problem even with a more potent compound - and not the technology